Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine

• Main Authors: Michele W. Tang, Soo Yon Rhee, Silvia Bertagnolio, Nathan Ford, Susan Holmes, Kim C. Sigaloff, Raph L. Hamers, Tobias F.Rinke De Wit, Herve J. Fleury, Phyllis J. Kanki, Kiat Ruxrungtham, Claudia A. Hawkins, Carole L. Wallis, Wendy Stevens, Gert U. Van Zyl, Weerawat Manosuthi, Mina C. Hosseinipour, Nicole Ngo-Giang-Huong, Laurent Belec, Martine Peeters, Avelin Aghokeng, Torsak Bunupuradah, Sherri Burda, Patricia Cane, Giulia Cappelli, Charlotte Charpentier, Anoumou Y. Dagnra, Alaka K. Deshpande, Ziad El-Katib, Susan H. Eshleman, Joseph Fokam, Jean Chrysostome Gody, David Katzenstein, Donato D. Koyalta, Johnstone J. Kumwenda, Marc Lallemant, Lutgarde Lynen, Vincent C. Marconi, Nicolas A. Margot, Sandrine Moussa, Thumbi Ndung'U, Phillipe N. Nyambi, Catherine Orrell, Jonathan M. Schapiro, Rob Schuurman, Sunee Sirivichayakul, Davey Smith, Maria Zolfo, Michael R. Jordan, Robert W. Shafer
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878329003&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/52849
• Institution: Chiang Mai University

Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary can...